LifeMD Divests WorkSimpli, Eyes 42% Upside to $10 on Telehealth Push
LifeMD Inc divested WorkSimpli to focus on telehealth and pharmacy services, trading at 0.796x trailing sales and launching the Wegovy pill to bolster its GLP-1 vertical. Loop Capital set a $10 price target implying 42% upside from $3.88, while the stock trades near $3.87 with a $186.3 million market cap.
1. Strategic Divestiture of WorkSimpli
LifeMD recently completed the sale of its WorkSimpli unit to sharpen its focus on core telehealth and pharmacy offerings, aiming to streamline operations and capture greater market share in virtual healthcare services.
2. $10 Price Target Signals 42% Upside
Loop Capital Markets assigned a $10 price target, suggesting roughly 42% upside from recent trading levels around $3.88, reflecting confidence in the company’s refocused strategy and growth prospects.
3. Low Valuation at 0.8x Sales
The stock trades at just 0.796 times trailing twelve-month sales, well below peer averages, implying potential for multiple expansion if revenue growth accelerates; shares change hands near $3.87 with a $186.3 million market cap.
4. Wegovy Launch Fuels GLP-1 Expansion
The company’s launch of the Wegovy pill marks its entry into the GLP-1 therapy market, expected to drive prescription volumes and revenue growth by leveraging its telehealth pharmacy platform.